Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalCardiologyDevice TherapyTrial Update

Trial on S-ICD Implantation Without Defibrillation Testing Shows Non-Inferiority

The trial results on S-ICD implantation without defibrillation testing could significantly influence clinical practices and device adoption in cardiology. If proven non-inferior, this approach may lead to a shift towards less invasive procedures, affecting market dynamics and competitive positioning.

Published: June 17, 2026
Updated: June 17, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Device Therapy
Company: Medtronic
Asset: Cardiology
Trial SummaryCLN

Phase III

Cardiology / Device Therapy

Status

Active

Sponsor

Medtronic

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The trial results on S-ICD implantation without defibrillation testing could significantly influence clinical practices and device adoption in cardiology. If proven non-inferior, this approach may lead to a shift towards less invasive procedures, affecting market dynamics and competitive positioning.

Why it matters

The trial results on S-ICD implantation without defibrillation testing could significantly influence clinical practices and device adoption in cardiology. If proven non-inferior, this approach may lead to a shift towards less invasive procedures, affecting market dynamics and competitive positioning.

What changed

Trial Update

Analysis

A randomized trial is assessing whether S-ICD implantation without defibrillation testing is non-inferior to the standard method.

The trial results on S-ICD implantation without defibrillation testing could significantly influence clinical practices and device adoption in cardiology. If proven non-inferior, this approach may lead to a shift towards less invasive procedures, affecting market dynamics and competitive positioning.

Monitor trial results and subsequent guidelines from cardiology associations regarding S-ICD implantation practices.

Related companies & assets

Companies

  • View signals for Medtronic →

Assets

  • Cardiology →

Sources & Humanexa intelligence

Source links

  • A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing ↗
  • Trial on S-ICD Implantation Without Defibrillation Testing Shows Non-Inferiority ↗

Related Humanexa pages

  • Trial on S-ICD Implantation Without Defibrillation Testing Shows Non-Inferiority →

Related signals

Trial SummaryCLN

Phase III

Oncology / Breast Cancer

Status

Active

Sponsor

Roche

Signal Score

8.2

Clinicalhigh signal

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

June 18, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / BRAF/MEK Inhibitors

Status

Initiated

Sponsor

Novartis

Signal Score

8.2

Clinicalhigh signal

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

June 18, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.